Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs United States Copper Index Fund (CPER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs United States Copper Index Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.04 (market cap $29.60B), while United States Copper Index Fund trades at $40.28. The key difference: United States Copper Index Fund is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CPER | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $491.22 | $40.85 |
52-Week Low | $205.48 | $27.57 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
CPER (United States Copper Index Fund) trades at $40.345, up 0.41% with a bullish technical signal supported by moving averages. The copper market faces supply constraints from Chilean weather disruptions while AI and electrification demand drives prices to record highs. Recent news highlights copper's structural bull case with Citi targeting $15,000/tonne by year-end.
Copper's fundamental outlook remains strong due to AI infrastructure demand and supply constraints, though substitution risks and geopolitical tensions present headwinds. The ETF offers pure copper exposure amid favorable analyst sentiment, with technical indicators suggesting continued upward momentum near key resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →
